Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Repatha effective; question is for which patients–FDA

[Reuters] – Amgen Inc’s experimental drug Repatha lowered cholesterol in clinical trials and did not cause a marked disparity in deaths or serious adverse events but showed potential safety issues that should be . . . → Read More: Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Repatha effective; question is for which patients–FDA Similar Articles: Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug